Status:

Do Not Prescribe (DNP), Red, Green

Decision Date:

February 2019

Comments

Prescribe by brand.

Subcutaneous preparation:

Ozempic 

GREEN - Ozempic is the preferred weekly GLP1 for type 2 diabetes. Use in patients who require a weekly GLP1 preparation.

Use of weekly preparation include:

1. if compliance is an issue or
2. if the patient requires regular visits from a nursing team to administer the drug

See local type 2 guidance. Semaglutide has the added benefit of positive cardiovascular outcomes in clinical trials. (Decision date - Dec 2022)

Wegovy 

GREEN*:  NICE TA1152 - Semaglutide (Wegovy) for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity. 

• Only to be used in line with NICE TA1152 in those with a BMI ≥ 27 kg/m2 AND a previous myocardial infarction, ischaemic or haemorrhagic stroke or symptomatic peripheral arterial disease. Semaglutide should be used alongside a reduced-calorie diet and increased physical activity.

*Work is ongoing to resolve implementation challenges, including service delivery arrangements and workforce implications. For more information, see August 2026 Decision and Justification Log 

RED: NICE TA875 - Wegovy is the preferred brand for managing overweight and obesity in adults. (Decision date - April 2023)

DNP: NICE TA910 - Semaglutide (Wegovy) for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal). (Decision date - Aug 2023)

 

Oral preparation:

GREEN - Rybelsus once daily oral preparation for type 2 diabetes (Decision date - February 2024)  

• GLP-1s to be used as per NICE NG28 for further intensification.
• oral semaglutide is taken on an empty stomach and at least 30 minutes before eating or taking other medicines. 

Do Not Prescribe (DNP) Drug Classifications

• 6: Have NICE guidance that recommends they should not be used

search again